tebentafusp
Generic: tebentafusp·Brand: Kimmtrak
tebentafusp: sourced relationships with 1 company · 1 clinical trial tracked.
tebentafusp evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect tebentafusp to IMCR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could tebentafusp → IMCR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Immunocore Holdings plc (IMCR) unresectable or metastatic uveal melanoma | Approved |
| Immunocore Holdings plc (IMCR) Select Advanced Solid Tumors | Phase 3 |
Clinical Trial Registry Records (1)
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Primary endpoint: Recurrence-Free survival (RFS)
InterventionalRandomizedopen290 targetStarted 2024-11Completion 2032-1115 sites · Belgium, France, Germany, Netherlands…European Organisation for Research and Treatment of Cancer - EORTC
Frequently asked questions
Which companies have sourced relationships with tebentafusp?
tebentafusp has dated SEC/FDA relationship records for Immunocore Holdings plc.
How many clinical trials involve tebentafusp?
BioSniper tracks 1 clinical trial involving tebentafusp.